CABALETTA BIO, INC. Interest Expense
CABALETTA BIO, INC. (CABA) reported Interest Expense of $517.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-08-13
- CABALETTA BIO, INC. interest expense for the quarter ending 2026-06-30 was $517.00K, a 9.46% decline year-over-year.
- CABALETTA BIO, INC. interest expense for the quarter ending 2026-03-31 was $636.00K, a 116.33% increase year-over-year.
- CABALETTA BIO, INC. interest expense for the quarter ending 2025-12-31 was $555.00K, a 25.80% decline year-over-year.
- CABALETTA BIO, INC. interest expense for the quarter ending 2025-09-30 was $584.00K.
- CABALETTA BIO, INC. interest expense for fiscal 2025 was $2.00M, a 167.91% increase from fiscal 2024.
- CABALETTA BIO, INC. interest expense for fiscal 2024 was $748.00K.
- CABALETTA BIO, INC. interest expense for fiscal 2023 was $0.00.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $517.00K 10-Q · filed 2026-08-13 | $1.15M 10-Q · filed 2026-08-13 | $1.71M derived: sum of 3 quarters · filed 2026-08-13 | $2.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $636.00K 10-Q · filed 2026-05-14 | $1.19M derived: sum of 2 quarters · filed 2026-05-14 | $1.77M derived: sum of 3 quarters · filed 2026-05-14 | $2.35M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $555.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.14M derived: sum of 2 quarters · filed 2026-03-23 | $1.71M derived: sum of 3 quarters · filed 2026-08-13 | $2.00M 10-K · filed 2026-03-23 |
| 2025-09-30 | $584.00K 10-Q · filed 2025-11-10 | $1.16M derived: sum of 2 quarters · filed 2026-08-13 | $1.45M 10-Q · filed 2025-11-10 | $2.20M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $571.00K 10-Q · filed 2026-08-13 | $865.00K 10-Q · filed 2026-08-13 | $1.61M derived: sum of 3 quarters · filed 2026-08-13 | $1.61M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $294.00K 10-Q · filed 2026-05-14 | $1.04M derived: sum of 2 quarters · filed 2026-05-14 | $1.04M derived: sum of 3 quarters · filed 2026-05-14 | $1.04M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $748.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $748.00K derived: sum of 2 quarters · filed 2026-03-23 | $748.00K derived: sum of 3 quarters · filed 2026-03-23 | $748.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |